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Rapid Communication
The calcimimetic cinacalcet normalizes serum calcium in
renal transplant patients with persistent hyperparathyroidism
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Abstract
Background. Treatment of persistent hyperparathy-
roidism in renal transplant patients resistant to calcium
and vitamin D sterols is limited and often requires
parathyroidectomy. Given the potential hazards
linked to surgery, an alternative approach to manage
excess parathyroid hormone (PTH) secretion is needed.
Calcimimetics inhibit PTH secretion by modulating the
calcium-sensing receptor in the parathyroid. Lowering
of the serum calcium concentration with the calcimi-
metic cinacalcet has previously been demonstrated in
patients with primary hyperparathyroidism or with
secondary hyperparathyroidism on dialysis. Here we
present the ﬁrst clinical observations of a calcimimetic
in patients with persistent hyperparathyroidism.
Methods. A 30mg dose of cinacalcet was prescribed
once daily for 3 months to seven female and seven male
stable renal transplant patients, aged 23–65 years,
7 months to 14 years after transplantation, with a
serum creatinine ranging from 89 to 229 mmol/l and
persistent hyperparathyroidism. Concomitant medica-
tion included cyclosporin and low-dose prednisone in
all patients.
Results. On cinacalcet, serum calcium decreased and
normalized in all but two patients (baseline 2.72±
0.03mmol/l; 1 month 2.42±0.04mmol/l, P<0.001),
whereas serum PTH and phosphate levels did not
change signiﬁcantly. A slight reduction in renal
function, as assessed by serum creatinine concentra-
tion, was observed at months 2 and 3 (P<0.05). An
immunoglobulin-deﬁcient patient developed colitis
after 1 week of treatment and cinacalcet was with-
drawn. No patient stopped cinacalcet because of other
presumed side effects.
Conclusion. Calcimimetics are a promising therapy in
renal transplant patients with persistent hyperpara-
thyroidism. Prospective controlled studies must now
be designed focusing on functionally relevant musculo-
skeletal end-points and allowing the exclusion of
negative effects on long-term renal and general out-
come of such patients.
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Introduction
Secondary hyperparathyroidism is a common compli-
cation of renal failure and end-stage renal disease.
Despite normalization of renal function and normal
concentrations of 1,25-dihydroxyvitamin D3 after
renal transplantation, elevated parathyroid hormone
(PTH) concentrations often persist, leading to mark-
edly increased serum calcium levels, an enhanced
fractional excretion of phosphate in the urine and
decreased bone mass [1,2]. This condition is due to
glandular hyperplasia and autonomous PTH produc-
tion, in part attributable to monoclonality [3]. In about
one-third of the patients, hyperparathyroidism does
not completely resolve even after several years of
successful renal transplantation [4–6]. In these patients,
surgical treatment is often mandatory. In some of
these patients, a surgical intervention might be hazard-
ous and therefore a medical treatment would be of
interest.
A novel class of compounds called calcimimetics
increases the sensitivity of the calcium-sensing receptor
of the parathyroid cells to extracellular calcium
[7–9]. Recently the oral calcimimetic, cinacalcet HCl,
was introduced successfully into clinical practice.
Cinacalcet rapidly normalized serum calcium and
reduced PTH in patients with primary hyperpara-
thyroidism, an effect persistant through a follow-up
1 year [10,11]. In chronic haemodialysis patients
with secondary hyperparathyroidism, this compound
reduced plasma PTH concentrations together with a
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subsequent decline in plasma calcium and phosphate
[12–15]. So far, calcimimetics have not been prescribed
to patients after successful renal transplantation.
Therefore, we investigated the effect of cinacalcet in
stable renal transplant patients with persistent hyper-
parathyroidism.
Subjects and Methods
Fourteen stable renal transplant patients (seven male, seven
female, aged 23–65 years) with persistent hyperparathyroi-
dism, followed for 7 months to 14 years (median 3.5 years)
after renal transplantation, were treated with cinacalcet. All
patients were followed in our unit. Persistent hyperparathy-
roidism was deﬁned by increased serum calcium concentra-
tions in the presence of increased PTH levels on dialysis,
not normalized 6 months after successful renal transplan-
tation despite normal or increased 1,25-dihydroxyvitamin
D3 levels.
All patients were treated with cyclosporin and doses of
prednisone <10mg/day. In addition, three patients were on
azathioprine, ﬁve on mycophenolate mofetil and one on
sirolimus. Before cinacalcet treatment, PTH levels ranged
from 80 to 1295 pg/ml (Figure 1). One patient with a high
normal value of 47 pg/ml was also treated because of
persistent hypercalcaemia between 2.6 and 2.7mmol/l in the
presence of 1,25-dihydroxyvitamin D3 levels ranging from
74 to 126 pmol/l.
Patients were given 30mg of oral cinacalcet once daily.
Out-patient visits were scheduled before and 1, 2 and 3months
after therapy was initiated. The following parameters were
assessed: creatinine, urea, potassium, calcium, phosphate and
PTH (intact) in serum, and cyclosporin trough levels in whole
blood; blood pressure; clinical events; and concomitant
medication. Repeated measurements of PTH before and 1,
2, 3 and 4 h after intake of cinacalcet were performed in two
patients.
Statistical analyses were executed using SYSTAT Version
12.0 (SYSTAT Software, Inc.). Paired Student’s t-test and
the Wilcoxon test for longitudinal non-parametric data were
used where applicable. All data given are means±SEM if not
otherwise indicated.
Results
Effect of cinacalcet on serum PTH, calcium
and phosphate
Serum PTH did not change in response to cinacalcet
administration. Although the data shown in Figure 1
suggest a decline for the entire population, due to the
large inter- and intra-individual variability in response
to the calcimimetic, this decline was not statistically
signiﬁcant. In order to better understand this varia-
bility, we measured the serum concentrations of PTH
before and 1, 2, 3 and 4 h following the intake of
cinacalcet in two patients on long-term therapy and
observed an acute decline (Figure 2). The trough levels
of PTH (concentrations in the morning before the
intake of cinacalcet) ranged between 55 and 130 pg/ml
in these two patients.
Serum total calcium concentrations declined in all
subjects after cinacalcet was given and remained stable
over the entire period of observation (P<0.001)
(Figure 1). In all patients except two, a normalization
of serum calcium below 2.55mmol/l was observed. In
one of these two patients, the serum calcium declined
from 2.71 to 2.63mmol/l and in the other from 2.71 to
2.60mmol/l. Mean serum phosphate concentrations
remained unchanged throughout the study period.
Before cinacalcet, one patient had hypophosphataemia
(0.54mmol/l), which disappeared with treatment. Two
patients experienced a slight hyperphosphataemia
between 1.65 and 1.77mmol/l while on the calcimi-
metic. The CaP product was not affected by cina-
calcet and the highest value observed was 4.27mmol/l2.
No consistent changes were detected with respect to the
fractional calcium and phosphate excretion and serum
alkaline phosphatase levels (results not shown).
Clinical observations
During the treatment period, the immunosuppressive
regimen remained unchanged. The whole blood trough
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Fig. 1. Serum concentrations of PTH, calcium and phosphate
before (month 0) and during treatment (months 1–3) with
cinacalcet (mean, SEM). Upper and lower limits of normal ranges
are depicted by dotted lines.
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concentrations of cyclosporin were not affected by
cinacalcet. At baseline, cyclosporin levels ranged
from 64 to 177 ng/ml, after 1 month of treatment
from 73 to 172 ng/ml, at 2 months from 51 to 131 ng/ml
and after 3 months from 80 to 181 ng/ml. With respect
to diuretic and antihypertensive therapy, only minor
changes occurred. In one patient, 20mg of furosemide
and in another 5mg of torasemide were withdrawn
2 months after therapy with cinacalcet was initiated.
None of the patients was on a calcium supplement.
Two patients received 0.5 and 1.75 mg/week of 1,25-
dihydroxyvitamin D3 for 2 months. Five patients
were additionally prescribed 1,25-dihydroxyvitamin
D3 (0.75–1.75 mg/week) at month 2.
Blood pressure remained unchanged during therapy
with cinacalcet (results not shown). The glomerular
ﬁltration rate, as assessed by serum creatinine concen-
trations, decreased during the observation period.
Serum creatinine concentrations were 140±15 mmol/l
at baseline, 139±16 mmol/l after 1 month, 153±
17 mmol/l after 2 months and 148±16 mmol/l after
3 months of treatment (P<0.05 at months 2 and 3).
One patient with a known immunoglobulin deﬁ-
ciency and recurrent intestinal disease developed severe
diarrhoea and colitis 1 week after cinacalcet had been
prescribed. Cinacalcet was withdrawn and the results
from the electrolyte and PTH measurements are not
considered for the present analysis. Another patient
experienced a myocardial infarction without arrhyth-
mia or complications after 2 months of treatment. The
patient received a percutaneous transluminal angio-
plast with stent implantation. She continued to take
cinacalcet thereafter and the results were included in
the present analysis. No patient stopped cinacalcet
because of other presumed side effects.
Discussion
Here we present the ﬁrst clinical observations in stable
renal transplant patients with persistent hyperpara-
thyroidism treated with a calcimimetic. These results
demonstrate that a low dose of cinacalcet given once
daily signiﬁcantly reduces the serum calcium concen-
tration. The decline in the PTH concentrations was
not signiﬁcant (Figure 1). This might be attributed
ﬁrst to the small number of subjects investigated,
and/or second to the peculiar pharmacokinetics/
pharmacodynamics of cinacalcet. Peacock and
co-workers recently analysed the pharmacodynamics
of cinacalcet in patients with primary hyperparathy-
roidism at week 24 of chronic prescription of cinacalcet
[10]. At 2 h after the morning dose of cinacalcet, they
observed a decline of PTH from 80 to 50 pg/ml. At
8 h, the PTH concentrations again reached the pre-
dose values. Peacock and co-workers estimated that
the area under the plasma concentration–time curve of
PTH over each 24 h cycle was reduced by 20% [10].
A similar rapid and transient response of PTH to the
administration of cinacalcet was reported for dialysis
patients with secondary hyperparathyroidism [16,17],
suggesting an immediate but transient effect of the
xenobiotic on PTH release. Thus, if the purpose of
cinacalcet prescription was to normalize not only the
serum calcium concentration, but also the area under
the concentration–time curve of PTH, the drug has to
be dosed at least twice a day in renal transplant
patients. Given the known beneﬁcial effects of PTH
for normal bone formation, it is unknown whether
normalization of PTH is a valid potential objective.
In addition to its effect on bone, PTH enhances
the urinary excretion of phosphate by regulating the
type IIa (Na2þ)/Pi co-transporter in the proximal
tubule [18]. In line with this effect, we observed a
normalization of the phosphate level in the only
hypophosphataemic patient and a slight hyperphos-
phataemia in two patients previously normophospha-
taemic. With cinacalcet treatment, the serum phosphate
concentrations increased by 10% in patients with
primary hyperparathyroidism [10,11], whereas in dia-
lysis patients these concentrations declined by 8%
[13]. The mechanism for the decrease of serum
phosphate concentrations in dialysis patients is
unknown. Thus, the effect of cinacalcet on serum
phosphate levels appears to be complex in patients
with kidney diseases and has to be taken into con-
sideration when this drug is prescribed. While hypo-
phosphataemia is a practically relevant issue after renal
transplantation and a reduced urinary excretion of
phosphate by the calcimimetic might be beneﬁcial,
hyperphosphataemia is more relevant in subjects with
a reduced glomerular ﬁltration rate. Therefore, special
attention has to be paid in the future to the changes of
the serum phosphate levels induced by calcimimetics
in renal transplant patients with a steadily changing
renal function.
In order to protect the bone from the unwarranted
effects of high PTH, parathyroidectomy is often
considered as a therapeutic option in patients with
persistent hyperthyroidism after renal transplantation.
Retrospective analyses revealed that such surgical
interventions might be associated with a decline in
the glomerular ﬁltration rate as assessed by serum
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Fig. 2. Serum PTH concentrations before (hour 0) and after dosing
of cinacalcet (hours 1–4) in two renal transplant patients on chronic
cinacalcet therapy.
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creatinine concentrations. For instance, Rostaing
and co-workers observed a signiﬁcant and persistent
increase in serum creatinine levels in eight out of
34 patients after parathyroidectomy, an effect par-
ticularly present in those patients presenting with
hypertension before surgery [19]. Lee and co-workers
followed 22 patients for 1 year after parathyroidectomy
and reported a steeper rise in serum creatinine after
surgery when compared with the 2 years before the
intervention. The effect of parathyroidectomy on the
serum calcium concentration was signiﬁcantly more
accentuated in patients exhibiting a worsening of graft
function after parathyroidectomy [20]. To the best of
our knowledge, it is unknown whether the decline
in renal function after surgery was attributable to the
intervention itself and/or to the changes of the mineral
metabolism induced by the removal of the parathyroid
glands. To answer this question, future prospective
studies comparing the impact on the serum creatinine
concentrations of a calcimimetic with that of para-
thyroidectomy might be useful. In our group of
patients, a slight increase in serum creatinine concen-
trations could be identiﬁed. However, the study
duration of 3 months does not allow characterization
of the long-term effects of cinacalcet treatment on renal
transplant function.
In conclusion, the calcimimetic cinacalcet is a
promising alternative to parathyroidectomy in patients
with persistent hyperparathyroidism after renal trans-
plantation. To exclude a negative impact of cinacalcet
on long-term renal or general outcome of kidney
transplant recipients, future studies should focus on
the glomerular ﬁltration rate of the allograft and
consider functionally relevant musculo-skeletal and
therapeutic endpoints.
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